William Blair Issues Positive Outlook for Repligen Earnings

Repligen Co. (NASDAQ:RGEN) – Equities research analysts at William Blair upped their FY2024 earnings per share estimates for shares of Repligen in a research report issued on Wednesday, December 11th. William Blair analyst M. Larew now anticipates that the biotechnology company will post earnings per share of $1.58 for the year, up from their prior estimate of $1.44. The consensus estimate for Repligen’s current full-year earnings is $1.52 per share. William Blair also issued estimates for Repligen’s Q4 2024 earnings at $0.45 EPS, Q1 2025 earnings at $0.38 EPS, Q2 2025 earnings at $0.46 EPS, Q3 2025 earnings at $0.45 EPS and Q4 2025 earnings at $0.50 EPS.

Repligen (NASDAQ:RGEN) last posted its quarterly earnings data on Tuesday, November 12th. The biotechnology company reported $0.43 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.34 by $0.09. Repligen had a positive return on equity of 3.90% and a negative net margin of 3.36%. The firm had revenue of $154.87 million for the quarter, compared to the consensus estimate of $153.34 million. During the same quarter in the previous year, the company earned $0.23 EPS. The business’s revenue for the quarter was up 9.7% compared to the same quarter last year.

A number of other analysts have also issued reports on RGEN. StockNews.com raised shares of Repligen from a “sell” rating to a “hold” rating in a research report on Friday, November 22nd. Royal Bank of Canada reiterated an “outperform” rating and issued a $205.00 target price on shares of Repligen in a research note on Thursday, September 26th. Wells Fargo & Company started coverage on shares of Repligen in a report on Tuesday, August 27th. They issued an “overweight” rating and a $180.00 price objective for the company. Finally, Wolfe Research began coverage on Repligen in a report on Thursday, November 14th. They set a “peer perform” rating on the stock. Four research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $190.25.

Repligen Stock Performance

Shares of RGEN stock opened at $156.41 on Friday. The stock’s fifty day simple moving average is $142.66 and its 200-day simple moving average is $141.66. The company has a market capitalization of $8.76 billion, a price-to-earnings ratio of -422.72, a P/E/G ratio of 4.67 and a beta of 0.96. The company has a current ratio of 10.44, a quick ratio of 8.76 and a debt-to-equity ratio of 0.26. Repligen has a 1-year low of $113.50 and a 1-year high of $211.13.

Institutional Investors Weigh In On Repligen

A number of institutional investors and hedge funds have recently made changes to their positions in the company. Andra AP fonden bought a new position in Repligen during the second quarter worth about $25,000. UMB Bank n.a. raised its position in shares of Repligen by 138.3% during the third quarter. UMB Bank n.a. now owns 224 shares of the biotechnology company’s stock worth $33,000 after purchasing an additional 130 shares during the period. Blue Trust Inc. lifted its holdings in shares of Repligen by 113.4% during the 3rd quarter. Blue Trust Inc. now owns 239 shares of the biotechnology company’s stock valued at $36,000 after purchasing an additional 127 shares in the last quarter. Resources Management Corp CT ADV bought a new stake in shares of Repligen during the third quarter worth $37,000. Finally, International Assets Investment Management LLC acquired a new position in Repligen during the second quarter worth $33,000. Institutional investors own 97.64% of the company’s stock.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.